Author

Shanna Maycock

Observed name: Maycock, Shanna

Institutions: Cancer Research UK Clinical Trials Unit, University of Birmingham

Observed institutions: Cancer Research UK Clinical Trials Unit, University of Birmingham

ORCID: 0000-0002-2457-8793

Observed ORCID: 0000-0002-2457-8793

OpenAlex ID: A5044063551

Selenium and Vitamin E for Prevention of Non–Muscle-Invasive Bladder Cancer Recurrence and Progression: A Randomized Clinical Trial

2023 · Richard T. Bryan, Sarah J. Pirrie, et al. · JAMA Network Open · 32

Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial

2024 · Brenda Gibson, Andre Baruchel, et al. · Blood · 12

Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial

2024 · Sridhar Chaganti, Shanna Maycock, et al. · Blood · 10

Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04)

2022 · John R Apps, Shanna Maycock, et al. · Neuro-Oncology Advances · 6

Risk-Stratified Sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-Novo Post-Transplant Lymphoproliferative Disorder: Results of the Tidal Trial

2021 · Sridhar Chaganti, Shanna Maycock, et al. · Blood · 6

Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial

2022 · Richard Dillon, Shanna Maycock, et al. · BMC Cancer · 5

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma (Glo-BNHL)

2023 · Emma Seaford, Shanna Maycock, et al. · Blood · 4

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

2020 · Andy C. Rawstron, Peter Hillmen, et al. · Blood · 4

Outcomes for Children with High Risk Acute Myeloid Leukemia on the Myechild 01 International Phase III Clinical Trial

2023 · Andrew Moore, Shanna Maycock, et al. · Blood · 3

Zanubrutinib monotherapy and combination therapy for relapsed and refractory primary CNS lymphoma (PRiZM+): study protocol for a multi-centre, open-label, Bayesian phase II platform trial

2026 · Graham McIlroy, Francesca Yates, et al. · BMC Cancer

A global study of novel agents in paediatric and adolescent relapsed and refractory B-cell non-Hodgkin lymphoma (Glo-BNHL): protocol for an adaptive international platform clinical trial

2026 · G. A. Amos Burke, Emma Seaford, et al. · BMC Cancer

Fludarabine and cytarabine is not superior to high dose cytarabine as consolidation therapy in standard risk AML in children: Results from the international Phase III MyeChild01 trial

2025 · Brenda Gibson, André Baruchel, et al. · Blood

A Novel Clinical Trial in Rare Paediatric B-Cell Non-Hodgkin Lymphoma: Evaluating the Glo-Bnhl Adaptive Bayesian Design Using Data from the Sparkle Trial

2024 · Shanna Maycock, Rui Qin, et al. · Blood

A Potential Paradigm for the Robust and Systematic Prioritisation of Assets in Academic-Led, Multi-Industry Collaborative Trials in Rare Populations (Glo-BNHL)

2023 · Emma Seaford, Nicole Scobie, et al. · Blood

Works count: 16

Citation count: 82

H-index: 5

I10-index: 3